EBS EBS エマ―ジェント・バイオソリュ―ションズEBSのチャート
EBSの企業情報
| symbol | EBS |
|---|---|
| 会社名 | Emergent BioSolutions Inc （EBS エマ―ジェント・バイオソリュ―ションズ） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 エマージェント・バイオソリューションズ（Emergent BioSolutions Inc.）は生命科学会社である。同社は偶発的かつ自然発生的な公衆衛生上の脅威に対処する専門製品を民間人および軍人へ提供することを通じて生命健康の保護と強化に集中する。同社は公衆衛生脅威（PHTs）に対処する医療対策の開発、製造、商業化の集中する。PHTsは化学、生物、放射線、核及び爆発的な脅威と新たな感染症、２つのカテゴリで展開する。同社はワクチンと抗感染薬、抗体療法、デバイスと契約製造、四つのビジネスユニットで事業を展開する。ワクチンと抗感染薬ユニット炭疽病の一般的な予防および曝露後の予防用のBioThraxを含む。デバイスビジネスユニットは反応性皮膚除染ローションキット（RSDL）とトロビガード（硫酸アトロピン、塩化オビドキシム）などの市販されている製品を含む。 エマ―ジェント・バイオソリュ―ションズは米国の製薬メ―カ―。医療ニ―ズと新興の健康への脅威に対処する製品を開発、製造。感染症の炭疽菌などバイオテロや生物戦の可能性のある薬剤対策の開発・供給を政府支援で行う。市販されている主な製品は「BioThrax」。その他、慢性リンパ球性白血病など腫瘍学対象の臨床を展開中。 Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated to providing solutions that address public health threats. Through social responsibility, Emergent BioSolutions aims to build healthier and safer communities. The company aspires to deliver peace of mind to theis patients and customers so they can focus on what's most important in their lives. In working together, Emergent envisions protecting or enhancing 1 billion lives by 2030. |
| 本社所在地 | 400 Professional Drive Suite 400 Gaithersburg MD 20879 USA |
| 代表者氏名 | Fuad El-Hibri |
| 代表者役職名 | Executive Chairman of the Board |
| 電話番号 | +1 240-631-3200 |
| 設立年月日 | 35916 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 1705人 |
| url | www.emergentbiosolutions.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 152.00000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 2586.62400 |
| 売上高 | 売上高（百万ドル） 782.40000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 3269.02400 |
| 当期純利益 | 当期純利益（百万ドル） 58.40000 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Emergent Biosolutions Inc revenues increased 39% to $782.4M. Net income before extraordinary items decreased 29% to $58.4M. Revenues reflect Product sales increase of 44% to $606.5M Contract manufacturing increase of 43% to $98.9M Contracts and grants increase of 9% to $77M. Net income was offset by Research and Development increase of 47% to $142.8M (expense). |
EBSのテクニカル分析
EBSのニュース
TPI Composites, Inc. (NASDAQ:TPIC), Emergent BioSolutions Inc. (NYSE:EBS) – Tiling stocks 2023/03/01 13:26:21 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post TPI Composites, Inc. (NASDAQ:TPIC), Emergent BioSolutions Inc. (NYSE:EBS) – Tiling stocks appeared first on Stocks Equity .
Why Emergent BioSolutions Stock Tumbled by Almost 12% Today 2023/02/28 21:51:00 The Motley Fool
It''s not a good day for investors when their company reports a shocking plunge into the red.
Emergent BioSolutions PT Lowered to $21 at Singular Research 2023/02/28 18:39:01 Investing.com
https://www.investing.com/news/pro/emergent-biosolutions-pt-lowered-to-21-at-singular-research-432SI-3017426
Emergent BioSolutions Inc. 2022 Q4 - Results - Earnings Call Presentation 2023/02/28 04:08:15 Seeking Alpha
The following slide deck was published by Emergent BioSolutions Inc.
Emergent BioSolutions Inc. (EBS) Q4 2022 Earnings Call Transcript 2023/02/28 04:01:06 Seeking Alpha
Emergent BioSolutions Inc. (NYSE:NYSE:EBS) Q4 2022 Earnings Conference Call February 27, 2023 5:00 PM ETCompany ParticipantsBob Burrows - Vice President, Investor RelationsBob Kramer -…
After A 19.47% Jump In The Last Week, Does Emergent BioSolutions Inc. (NYSE: EBS) Still Make Sense To Buy? 2022/06/25 13:30:00 Marketing Sentinel
During the last session, Emergent BioSolutions Inc. (NYSE:EBS)’s traded shares were 0.78 million, with the beta value of the company hitting 1.02. At the end of the trading day, the stock’s price was $32.76, reflecting an intraday gain of 1.30% or $0.42. The 52-week high for the EBS share is $68.03, that puts it down … After A 19.47% Jump In The Last Week, Does Emergent BioSolutions Inc. (NYSE: EBS) Still Make Sense To Buy? Read More »
Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada 2022/06/24 14:06:00 GlobeNewswire
DURHAM, N.C., June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Public Health Agency of Canada awarded Chimerix a contract up to $25.3 million agreement to procure TEMBEXA ® (brincidofovir). Execution of this contract will be the responsibility of Chimerix, as it is expected to substantially occur prior to the close of the pending transaction with Emergent BioSolutions, Inc. (Emergent).
UPDATE: Emergent BioSolutions says FDA has accepted its anthrax vaccine candidate for review 2022/06/24 11:16:34 MarketWatch
Emergent BioSolutions Inc. undefined said Friday the U.S. Food and Drug Administration has accepted for review its application for approval of its anthrax…
EBS stock in focus as FDA accepts marketing application for anthrax vaccine (NYSE:EBS) 2022/06/24 11:06:10 Seeking Alpha
Emergent BioSolutions (EBS) announced on Friday that the FDA accepted its Biologics License Application ((BLA)) for the investigational anthrax vaccine AV7909 with a Prescription Drug…
Emergent BioSolutions says FDA has accepted its anthrax vaccine candidate for review 2022/06/24 10:39:06 MarketWatch
Emergent BioSolutions Inc. said Friday the U.S. Food and Drug Administration has accepted for review its application for approval of its anthrax vaccine. Dubbed AV7909, the vaccine is aimed at people aged 18 through 65 years who have been exposed to anthrax for use along with recommended antibacterial drugs. A decision is expected by April of 2023. "As we progress toward licensure of AV7909, which is designed to follow a two-dose immunization schedule and to elicit a faster immune response, we redouble our efforts to support the government''s overall preparedness and response strategy for large-scale emergencies involving anthrax and other threats to public health," said Kelly Warfield, Emergent senior vice president for R&D, in a statement. The company has submitted data from a phase 3 clinical trial of the vaccine, as well as from a phase 2 trial. Emergent shares were down 3% premarket and have fallen 26% in the year to date, while the s&P500 has fallen 20%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.
Fuad El-Hibri, Who Led a Troubled Vaccine Maker, Dies at 64 2022/04/30 19:09:09 New York Times
His company, Emergent BioSolutions, won a lucrative contract to produce Covid vaccines but then had to throw out millions of contaminated doses.
Emergent BioSolutions (EBS) Q1 2022 Earnings Call Transcript 2022/04/29 22:30:40 The Motley Fool
EBS earnings call for the period ending March 31, 2022.
Emergent BioSolutions Inc. 2022 Q1 - Results - Earnings Call Presentation (NYSE:EBS) 2022/04/29 21:01:53 Seeking Alpha
The following slide deck was published by Emergent BioSolutions Inc.
Emergent BioSolutions Suspends CDMO Guidance As It Awaits Clarity On COVID-19 Vaccine Requirements 2022/04/29 19:05:06 Benzinga
Emergent BioSolutions Inc (NYSE: EBS ) reported Q1 sales of $307.5 million , down 10% Y/Y, beating the consensus of $283 million. Total product sales increased 72% to $237.1 million, while Contract development & manufacturing (CDMO) revenues declined 67% to $60.8 million. The decrease is primarily due to the company''s decision to initiate maintenance … Full story available on Benzinga.com
Emergent BioSolutions dips on lowered price target at Cowen amid lowering Narcan revenue guidance 2022/04/29 17:51:19 Seeking Alpha
Emergent BioSolutions (EBS) trades lower during the day''s trade after Cowen lowered price target to $30 from $40 while maintaining its Market Perform rating on the shares.Analyst…